Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Linagliptin in Improving Renal Failure by Improving CD34+ Stem Cell Number, Function and Gene Expression in Renal Function Impaired Type 2 Diabetes Patients.

NCT02467478 is registered in ClinicalTrials.gov with George Washington University as lead sponsor.

NCT NCT02467478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02467478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Linagliptin in Improving Renal Failure by Improving CD34+ Stem Cell Number, Function and Gene Expression in Renal Function Impaired Type 2 Diabetes Patients.
Lead sponsor
George Washington University
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2015
Completion date
December 31, 2019
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

impaired renal function, type 2 diabetes